A61P 19 - Drugs for skeletal disorders

Patents for A61P 19 - Drugs for skeletal disorders (81,981)
10/2001
10/17/2001	EP1144450A1 Mammalian alpha-helical protein - 12
10/17/2001	EP1144443A2 Human membrane transport proteins
10/17/2001	EP1144441A2 Disintegrin homologs
10/17/2001	EP1144431A2 16-hydroxyestratrienes as selective estrogens
10/17/2001	EP1144421A1 Phosphinic pseudopeptides inhibitors of matrix metalloproteases
10/17/2001	EP1144409A2 Phenyl urea and phenyl thiourea derivatives
10/17/2001	EP1144403A1 Substitued pyrazoles as p38 kinase inhibitors
10/17/2001	EP1144402A2 Substituted oximes and hydrazones as neurokinin antagonists
10/17/2001	EP1144396A2 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
10/17/2001	EP1144394A1 1-heterocycle substituted diarylamines
10/17/2001	EP1144393A2 Heterocyclic derivatives and their use as integrin inhibitor
10/17/2001	EP1144390A2 Kinase inhibitors
10/17/2001	EP1144385A1 Benzoheterocycles and their use as mek inhibitors
10/17/2001	EP1144372A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
10/17/2001	EP1144371A1 Benzenesulphonamide derivatives and their use as mek inhibitors
10/17/2001	EP1144370A2 Thyroid receptor ligands
10/17/2001	EP1144369A2 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
10/17/2001	EP1144364A2 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
10/17/2001	EP1144362A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
10/17/2001	EP1144348A2 Lta 4? hydrolase inhibitors
10/17/2001	EP1144305A1 NOVEL sPLA 2 INHIBITORS
10/17/2001	EP1144008A1 Modulation of systemic memory t cell trafficking
10/17/2001	EP1144003A1 Methods and devices for delivery of agents to breast milk ducts
10/17/2001	EP1143985A2 Use of lactobacillus salivarius
10/17/2001	EP1143984A1 Egg anti-inflammatory composition and method of treating and preventing inflammation
10/17/2001	EP1143965A1 Carbocyclic potassium channel inhibitors
10/17/2001	EP1143964A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
10/17/2001	EP1143961A2 Regulators of the ptc or smoothened pathway, compositions and uses related thereto
10/17/2001	EP1143960A2 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
10/17/2001	EP1143957A2 Treatment of arthritis with mek inhibitors
10/17/2001	EP1143949A2 19-nor-vitamin d3 compounds with calcemic activity
10/17/2001	EP1143947A2 Use of estrogen compounds for prevention and treatment of ischemic damage
10/17/2001	EP1143946A2 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
10/17/2001	EP1143944A2 Use of arylalkanoylpyridazines
10/17/2001	EP1143932A1 Transnasal transport/immunisation with highly adaptable carriers
10/17/2001	EP1143920A1 Oil-in-water emulsion comprising a micronised biologically active agent and an appropriate emulsifier system
10/17/2001	EP1143806A2 Method for increasing pet activity
10/17/2001	CN1318105A Methods for down-regulating osteoprotegerin ligand activity
10/17/2001	CN1318059A Isoquinolines as urokinase inhibitors
10/17/2001	CN1318054A Novel compounds
10/17/2001	CN1317321A Medicine for treating intractable ischias and chronic lumbocrural pain and its preparing process
10/17/2001	CN1317319A Ointment for treating bone injury and its preparing process
10/17/2001	CN1073154C Superoxide dismutase-4
10/17/2001	CN1072947C Medicine for curing waist sprain and contusion
10/16/2001	US6303789 Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
10/16/2001	US6303659 Administering adamantane derivative for therapy of rheumatoid arthritis
10/16/2001	US6303653 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
10/16/2001	US6303636 Arylsulfonylamino hydroxamic acid derivatives
10/16/2001	US6303602 Useful as analgesic, anesthetic, anti-inflammatory or neuroprotective agent, or for therapy of arthritis, stroke of functional bowel disease
10/16/2001	US6303601 Arylgycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds
10/16/2001	US6303585 Cross-linked polysaccharide drug carrier
10/16/2001	US6303314 T-cell receptor Vβ-Dβ-Jβ sequence and methods for its detection
10/16/2001	US6303138 Endothelin-based compositions for enhancing connective tissue repair
10/16/2001	CA2096350C Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth)
10/13/2001	CA2344089A1 Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
10/11/2001	WO2001075170A1 A functional assay of high-density lipoprotein
10/11/2001	WO2001075168A1 Control of a gene induced by oxidized lipids in human artery wall cells
10/11/2001	WO2001075109A2 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability
10/11/2001	WO2001075108A1 Human ion channel protein and polynucleotides encoding the same
10/11/2001	WO2001075081A1 Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
10/11/2001	WO2001075078A1 HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
10/11/2001	WO2001075074A1 Novel proteins
10/11/2001	WO2001074903A2 CD20/IgE-RECEPTOR LIKE MOLECULES AND USES THEREOF
10/11/2001	WO2001074896A1 Human polynucleotides, polypeptides, and antibodies
10/11/2001	WO2001074841A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis
10/11/2001	WO2001074823A2 Fused heterocyclic derivatives, their production and use
10/11/2001	WO2001074811A2 Substituted 1,3-thiazole compounds, their production and use
10/11/2001	WO2001074806A1 Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
10/11/2001	WO2001074805A1 Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
10/11/2001	WO2001074780A1 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist
10/11/2001	WO2001074765A1 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
10/11/2001	WO2001074506A1 Extrusion die
10/11/2001	WO2001074410A1 Calcium phosphate artificial bone as osteoconductive and biodegradable bone substitute material
10/11/2001	WO2001074380A2 Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance
10/11/2001	WO2001074379A2 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
10/11/2001	WO2001074369A1 Divided dose therapies with vascular damaging activity
10/11/2001	WO2001074365A2 An efficacious dosage regimen of galantamine that reduces side effects
10/11/2001	WO2001074344A2 Small organic molecule regulators of cell proliferation
10/11/2001	WO2001074337A1 System for transporting active substances in a biological system
10/11/2001	WO2001074314A2 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
10/11/2001	WO2001074180A1 Nutritional supplements for stimulating bone growth
10/11/2001	WO2001066139A8 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell
10/11/2001	WO2001034572A3 Carboxamide-substituted benzimidazol derivatives, method for the production thereof and their use as tryptase inhibitors
10/11/2001	WO2001025269A3 Human g-protein coupled receptor
10/11/2001	WO2001024763A3 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
10/11/2001	WO2001021587A3 Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors
10/11/2001	WO2001021202A3 Treatment of chronic inflammatory disease by inhibiting sub-groups of activated t-cells
10/11/2001	WO2001007470A3 Human nervous system-associated proteins
10/11/2001	WO2000042429A3 In vitro model for gastrointestinal inflammation
10/11/2001	US20010029304 Cyclopentane heptan (ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
10/11/2001	EP1145001A3 (in vitro) model for gastrointestinal inflammation
10/11/2001	DE10013223A1 In vitro preparation of cartilage and bone tissue, useful for transplantation and for pharmaceutical testing, comprises culturing cells on hydrophobic surfaces to form aggregates
10/11/2001	CA2404896A1 Human ion channel protein and polynucleotides encoding the same
10/11/2001	CA2404576A1 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability
10/11/2001	CA2404484A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis
10/11/2001	CA2404413A1 Small organic molecule regulators of cell proliferation
10/11/2001	CA2404384A1 Substituted 1,3-thiazole compounds, their production and use
10/11/2001	CA2404350A1 Control of a gene induced by oxidized lipids in human artery wall cells
10/11/2001	CA2404074A1 Human polynucleotides, polypeptides, and antibodies
10/11/2001	CA2403885A1 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist

1 ... 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 ... 820